Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: A phase II study

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1325-1331

  Hillerdal, Gunnar ^a   Sorensen, Jens Benn ^b   Sundström, Stein ^c   Riska, Henrik ^d   Vikström, Anders ^e   Hjerpe, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b FINSEN LABORATORY   (Denmark)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Pleural mesothelioma; Survival; Treatment

Indexed keywords

ASBESTOS; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; LIPOSOME;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEPSIS; STOMATITIS; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; SURVIVAL RATE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; SURVIVAL RATE; TIME FACTORS;

EID: 58949097246     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818b174d     Document Type: Article

References (25)

1. Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007;369:844-849.
2. Hillerdal G. Malignant mesothelioma 1982. Review of 4710 published cases. Br J Dis Chest 1983;77:321-343.
3. Tammilehto L. Malignant mesothelioma: Prognostic factors in a prospective study of 98 patients. Lung Cancer 1992;8:175-184.
4. Chahinian P, Holland J. Treatment of diffuse malignant mesothelioma. A review. Mt Sinai J Med 1978;45:54-67.
5. Weissmann L, Antman K. Incidence, presentation and promising new treatments for malignant mesothelioma. Oncology 1989;3:67-72.
6. Krarup-Hansen A, Hansen H. cancer chemotherapy in malignant me-sothelioma: a review. Chemother Pharmacol 1991;28:319-330.
7. Mattson K, Holsti LR, Tammilehto L, et al. Multimodality treatment programmes for malignant pleural mesothelioma using high dose hemi-thorax irradiation. Int J Radiat Oncol Biol Phys 1992;24:643-650.
8. Uziely B, Jeffers S, Isacsson R, Kutsch K. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995;13:1777-1785.
9. Stewart S, Jablonowski H, Goebel FD, et al. Randomized Comparative trial of Pegylated Liposomal Doxorubicin versus Bleomycin and Vinc-ristin in the Treatment of AIDS-related Kaposi's Sarcoma. J Clin Oncol 1998;16:683-691.
10. Hillerdal G, Sorensen JB, Sundström S, Vikström A, Hjerpe A. Treatment of malignant pleural mesothelioma with liposomised doxorubicine: prolonged time to progression and good survival. A Nordic study. Clin Respir J 2008;2:80-85.
11. Baas P, van Meerbeck J, Groen H, et al. Caleyx in malignant mesothe-lioma: a phase I EORTC study. Ann Oncol 2000;11:697-700.
12. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239-242.
13. Raghavan D, Gianoutsous P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8: 151-154.
14. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and of Gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of Pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644.
16. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257- 260.
17. Van Haarst JMW, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-345.
18. Heinemann V. Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001;60:8-18.
19. Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thor Surg 2007;84:1685-1693.
20. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965.
21. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
22. Rusch VW, Rosenzwig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122: 788-795.
23. Lee TT, Everett DL, Shu HKG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124:1183-1189.
24. Lucchi M, Chella A, Melfi F, et al. Four-modality therapy in malignant pleural mesothelioma: a phase II study. J Thorac Oncol 2007;2:237- 242.
25. Treasure T. Editorial: Mesothelioma: benefit from surgical resection is questionable. J Thor Oncol 2007;2:885-886.